Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era
Patients with inflammatory bowel disease (IBD) are at an increased risk of developing intestinal neoplasia—particularly colorectal neoplasia, including dysplasia and colorectal cancer (CRC)—as a primary consequence of chronic inflammation. While the current incidence of CRC in IBD is lower compared...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-05-01
|
Series: | Therapeutic Advances in Gastroenterology |
Online Access: | https://doi.org/10.1177/1756284820920779 |
id |
doaj-29fc2ccb6a744386b2cf7e1ad3e2775e |
---|---|
record_format |
Article |
spelling |
doaj-29fc2ccb6a744386b2cf7e1ad3e2775e2020-11-25T03:36:02ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482020-05-011310.1177/1756284820920779Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern eraJordan E. AxelradShailja C. ShahPatients with inflammatory bowel disease (IBD) are at an increased risk of developing intestinal neoplasia—particularly colorectal neoplasia, including dysplasia and colorectal cancer (CRC)—as a primary consequence of chronic inflammation. While the current incidence of CRC in IBD is lower compared with prior decades, due, in large part, to more effective therapies and improved colonoscopic technologies, CRC still accounts for a significant proportion of IBD-related deaths. The focus of this review is on the pathogenesis; epidemiology, including disease- and patient-related risk factors; diagnosis; surveillance; and management of IBD-associated neoplasia.https://doi.org/10.1177/1756284820920779 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jordan E. Axelrad Shailja C. Shah |
spellingShingle |
Jordan E. Axelrad Shailja C. Shah Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era Therapeutic Advances in Gastroenterology |
author_facet |
Jordan E. Axelrad Shailja C. Shah |
author_sort |
Jordan E. Axelrad |
title |
Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era |
title_short |
Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era |
title_full |
Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era |
title_fullStr |
Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era |
title_full_unstemmed |
Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era |
title_sort |
diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era |
publisher |
SAGE Publishing |
series |
Therapeutic Advances in Gastroenterology |
issn |
1756-2848 |
publishDate |
2020-05-01 |
description |
Patients with inflammatory bowel disease (IBD) are at an increased risk of developing intestinal neoplasia—particularly colorectal neoplasia, including dysplasia and colorectal cancer (CRC)—as a primary consequence of chronic inflammation. While the current incidence of CRC in IBD is lower compared with prior decades, due, in large part, to more effective therapies and improved colonoscopic technologies, CRC still accounts for a significant proportion of IBD-related deaths. The focus of this review is on the pathogenesis; epidemiology, including disease- and patient-related risk factors; diagnosis; surveillance; and management of IBD-associated neoplasia. |
url |
https://doi.org/10.1177/1756284820920779 |
work_keys_str_mv |
AT jordaneaxelrad diagnosisandmanagementofinflammatoryboweldiseaseassociatedneoplasiaconsiderationsinthemodernera AT shailjacshah diagnosisandmanagementofinflammatoryboweldiseaseassociatedneoplasiaconsiderationsinthemodernera |
_version_ |
1724551729724260352 |